{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-23-000070","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.740418+00:00","generated_at":"2026-06-08T08:56:40.722688+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Supernus Q3 GAAP net loss $16M; raises FY adjusted op earnings guide to $95-110M","bullets":["Total revenues $153.9M; Qelbree net sales $37.1M (+103% YoY), GOCOVRI $32.9M (+18% YoY).","GAAP net loss of $16.0M ($0.29 diluted EPS); adjusted operating earnings $37.3M, up 47% YoY.","FY 2023 adjusted operating earnings guidance raised to $95-110M from $75-100M; total revenue guidance $590-610M.","FDA accepted SPN-830 NDA resubmission for Parkinson's; PDUFA date April 5, 2024.","Qelbree IQVIA prescriptions 163,344 (+73% YoY); prescriber base expanded to ~24,189."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-23-000070","json":"https://secwatch.observer/filing/0001356576-23-000070.json","markdown":"https://secwatch.observer/filing/0001356576-23-000070.md","text":"https://secwatch.observer/filing/0001356576-23-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000070/0001356576-23-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000070/supn-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:56:40.722688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cace511b235388d01d5c3c7c7ef11310663e66b9","claim":"SUPERNUS PHARMACEUTICALS, INC. updated its the third quarter ended September 30, 2023 guidance (raised).","evidence_excerpt":"On November 8, 2023, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2023. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657623000070/0001356576-23-000070-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}